Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 27;39(8):2307–2315. doi: 10.1007/s10067-020-04970-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — League table of pairwise comparisons for all treatments in the ASAS20 NMA. Pairwise comparisons are reported as ORs and 95% Crls. Comparators are ordered from largest (top-left) to smallest (bottom-right) SUCRA values for the ASAS20 NMA. Please refer to Fig. 5 for SUCRA values for each NMA. Superior improvements in ASAS20 are denoted in bold text and light gray cells. Results are shown for the baseline risk-adjusted model for ASAS20. Please refer to Appendix S6 for the model fit statistics. Abbreviations: ADA, adalimumab; APR, apremilast; ASAS20, improvement of ≥ 20% in the Assessment of Spondyloarthritis International Society Criteria; Crls, credible intervals; CZP, certolizumab pegol; ETN, etanercept; FIL, filgotinib; GOL, golimumab; IFX, infliximab; IXE, ixekizumab; IV, intravenous; LD, loading dose; NMA, network meta-analysis; OR, odds ratio; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; RIS, risankizumab; SC, subcutaneous; SEC, secukinumab; SUCRA, Surface Under the Cumulative Ranking curve; TOF, tofacitinib; UST, ustekinumab